Figure S1


A
TMEM16F Exon 2
TGTTGGAAAACCTTGGACAGACAATTGTCCCCGATTTGGG
ATCACTGGAAAGTCAGCATGATTTTCGAACCCCGGAGTTT
Exon 2 CRISPR gRNA Target
B
Control Vector Transduced - Exon 2
PCR Primer Set 1
PCR Primer Set 2
C
TMEM16F CRISPR Vector Transduced - Exon 2
PCR Primer Set 1
PCR Primer Set 2
D
Control Vector Transduced
...agtcagcatgattttcgaaccccggagtttgaagaatttaatgga...
S Q H D F R T P E F E E F N G
TMEM16F CRISPR Vector Transduced
...agtcagcatgattttcgaagccccggagtttga
S Q H D F R I P G V *
E
TMEM16F Exon 5
GTATTGGATGACAAGCTTGTATTTGTAAAAGTACACGCACCATGGGAG
GTGTTATGTACGTATGCTGAGATAATGCACATCAAATTGCCTCTGAAA
CCCAATGATCTGAAAAACCGGTCCTCAGCCTTTGGTACACTCAACTGG
TTTACCAAAGTCCTCAGTGTAGACGAAAGCATCATCAAGCCAGAGCAA
GAGTTTTTCACTGCCCCATTTGAGAAGAACCGGATGAATGATTTTTAC
ATAGTTGATAGAGATGCTTTCTTCAATCCAGCCACCAGAAGCCGCATT
Exon 5 CRISPR gRNA Target
F
Control Vector Transduced - Exon 5
PCR Primer Set 3
G
TMEM16F CRISPR Vector Transduced - Exon 5
PCR Primer Set 3
H
WT
TMEM16F-null Exon 2 Clone
TMEM16F-null Exon 5 Clone
% of Max
AnxV
Untreated
Ionomycin
Etoposide